Home / Stocks / Poly Medicure Limited
POLYMED

Poly Medicure Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,670.6

Change

+16.1 (0.97%)

Open

₹1,650.0

Prev. Close

₹1,654.5

Day High

₹1,675.0

Day Low

₹1,647.0

Volume Analysis

Traded

36,339

Delivered

20,252

Delivery %

55.73%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Promoter holding is rising
  • •Strong operating margin (23.0%)

Weaknesses (1)

  • •Low return on equity (9.8%)

Opportunities (2)

  • •Strong 3-year EPS growth (19.4%)
  • •Strong 3-year revenue growth (18.9%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,709.4 ₹1,692.2 ₹1,681.4 ₹1,664.2 ₹1,653.4 ₹1,636.2 ₹1,625.4
Fibonacci ₹1,692.2 ₹1,681.5 ₹1,674.9 ₹1,664.2 ₹1,653.5 ₹1,646.9 ₹1,636.2
Camarilla ₹1,678.3 ₹1,675.73 ₹1,673.17 ₹1,664.2 ₹1,668.03 ₹1,665.47 ₹1,662.9

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-4.13%

1 Week

-1.33%

1 Month

+13.64%

3 Months

-2.84%

6 Months

+4.53%

1 Year

-11.1%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹479.84

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

8.46%

Net margin 14.81% × asset turnover 0.45x × equity multiplier 1.27x

Company Overview

Sector

Healthcare

Market Cap

₹17,041 Cr

P/E (TTM)

53.9

ROE

9.8%

Book Value

₹322.0

Face Value

₹5.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Poly Medicure Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 63/100. The strongest factor is Financial Strength (100/100), while Valuation (18/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (23.0%); low return on equity (9.8%). FII holding has been falling.

TopFund Score — Fundamentals Quality

63/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

93

Valuation

18

Cash Flow

27

Corporate Governance

85

Momentum

59

Institutional Ownership

45

Business Quality

71

Risk & Volatility

43

Liquidity

49

From Screener.in

  • −Company has a low return on equity of 13.3% over last 3 years.
  • −Debtor days have increased from 83.9 to 103 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Poly Medicure to participate in Avendus Spark INDX annual investor conference on 18 November in Mumbai.

QIP monitoring report for quarter ended Sep 30, 2026; Rs98,534.37 lakh proceeds, Rs9,544.62 lakh capex used; project delayed.

Audio recording of 05 Nov 2026 earnings call for Q2 FY27 available on company website.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 337 340 378 385 420 424 441 403 444 494 535 525 581
Expenses + 253 249 282 281 305 310 321 298 329 382 424 400 443
Operating Profit 84 90 96 104 115 114 119 106 115 111 110 125 138
OPM % 25.0% 27.0% 26.0% 27.0% 27.0% 27.0% 27.0% 26.0% 26.0% 23.0% 21.0% 24.0% 24.0%
Other Income + 15 17 15 17 27 24 27 43 35 21 19 35 30
Interest 2 3 3 3 3 3 2 3 3 6 6 6 7
Depreciation 16 16 16 20 21 21 21 23 25 29 38 36 35
Profit before tax 81 88 92 98 118 113 123 123 122 98 85 117 125
Tax % 23.0% 26.0% 26.0% 25.0% 26.0% 25.0% 25.0% 24.0% 25.0% 27.0% 24.0% 27.0% 24.0%
Net Profit + 62 65 68 74 87 85 92 93 92 71 65 85 95
EPS in Rs 6 7 7 8 9 8 9 9 9 7 7 8 9
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 23 19 23 20 25 25 17 5 6 16 21 30 31

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 390 411 454 519 610 687 785 922 1,115 1,375 1,669 1,875 2,134
Expenses + 304 323 361 397 479 520 569 707 847 1,014 1,213 1,429 1,650
Operating Profit 86 88 93 122 131 166 216 215 267 361 456 446 484
OPM % 22.0% 21.0% 21.0% 23.0% 22.0% 24.0% 28.0% 23.0% 24.0% 26.0% 27.0% 24.0% 23.0%
Other Income + 28 8 14 16 20 21 22 40 38 60 94 119 106
Interest 10 10 8 12 14 20 11 6 11 14 14 21 26
Depreciation 19 21 24 29 37 41 48 54 57 63 83 116 138
Profit before tax 85 65 75 97 100 126 180 195 237 344 453 427 426
Tax % 27.0% 27.0% 27.0% 27.0% 35.0% 24.0% 25.0% 25.0% 25.0% 25.0% 25.0% 25.0% —
Net Profit + 62 48 55 71 65 96 136 147 179 258 339 321 316
EPS in Rs 7 5 6 8 7 11 14 15 19 27 33 32 31
Dividend Payout % 18.0% 27.0% 40.0% 25.0% 27.0% 18.0% 18.0% 16.0% 16.0% 11.0% 10.0% 11.0% —
Sales growth 21 6 10 14 18 13 14 17 21 23 21 12 25

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 174 207 227 294 337 391 918 1,040 1,194 1,422 2,715 3,055 3,215
Borrowings + 79 82 101 133 161 207 137 127 149 174 180 354 412
Other Liabilities + 89 76 85 94 112 126 121 163 187 215 246 401 478
Total Liabilities 364 387 457 565 654 767 1,224 1,377 1,577 1,859 3,192 3,861 4,155
Fixed Assets + 165 182 207 265 306 363 426 488 635 867 1,084 1,694 1,861
CWIP 10 14 20 18 19 25 21 43 78 76 101 99 110
Investments 4 4 3 17 8 25 354 346 126 167 1,076 755 746
Other Assets + 185 187 227 264 321 354 422 499 738 748 930 1,313 1,438
Total Assets 364 387 457 565 654 767 1,224 1,377 1,577 1,859 3,192 3,861 4,155
Equity Capital 22 22 44 44 44 44 48 48 48 48 51 51 51

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 63 63 56 75 106 131 119 123 191 266 233 246
Cash from Investing Activity + -59 -31 -56 -88 -101 -109 -436 -85 -179 -241 -1,187 -224
Cash from Financing Activity + -6 -31 0 16 -5 -21 317 -35 -13 -20 951 20
Net Cash Flow -2 1 0 3 1 1 0 3 -1 5 -3 43
Free Cash Flow 13 31 0 -7 31 25 24 -31 -48 -9 -97 -59
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 101 88 79 80 102 100 75 80 93 94 71 78

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 53.17% → 62.41%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 27.28% 27.25% 14.72% 13.23% 13.57% 14.13% 14.43% 14.28% 14.34% 16.08% 15.94% 16.33%
Promoters 53.17% 53.14% 66.02% 62.56% 62.44% 62.44% 62.44% 62.42% 62.42% 62.42% 62.42% 62.41%
FII 14.1% 12.37% 9.91% 11.88% 12.33% 11.46% 11.41% 9.77% 9.41% 5.92% 5.56% 5.36%
DII 5.46% 7.21% 9.34% 12.33% 11.66% 11.96% 11.72% 13.53% 13.84% 15.6% 16.08% 15.9%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Poly Medicure Limited (this stock) 17,041 53.9 5.22 9.8%
Molbio Diagnostics Ltd 17,111 236.0 11.89 15.6%
Dr Agarwals Health Care L 17,460 97.5 7.8 6.41%
Cohance Lifesciences Ltd 17,511 359.0 4.49 4.89%
Pfizer Ltd 17,601 115.0 12.74 19.8%
Shilpa Medicare Ltd 17,616 55.1 6.39 9.3%
Alivus Life Sciences Ltd 17,803 50.6 — —

Which Mutual Funds Hold Poly Medicure Limited?

Frequently Asked Questions about Poly Medicure Limited

Community Sentiment

What are other investors saying about Poly Medicure Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.